- Analysis showed improvement in muscle morphology and increased
levels of regeneration in muscle groups, including the diaphragm,
quadriceps, and calf
- No adverse events and no significant changes in hematology or
clinical chemistry were observed after four months of daily, oral
treatment with SAT-3247, Satellos’ proprietary small molecule
- Data to be presented at the 2024 World Muscle Society Annual
Congress
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX:
MSCL, OTCQB: MSCLF), a public biotech company developing new small
molecule therapeutic approaches to improve the treatment of muscle
diseases and disorders, today announced a presentation of data at
the 29th Annual Congress of the World Muscle Society taking place
October 8-12, 2024, in Prague. The presentation will provide an
overview of key data collected during the open-label pilot study of
SAT-3247 in a canine model of Duchenne muscular dystrophy
(“Duchenne” or “DMD”).
An initial summary of the data is presented below. After four
months of treatment with SAT-3247:
- Treated animals showed a return to muscle function near
healthy, non-diseased, age-matched animal levels when evaluated
against historical comparator data.
- The animals showed increases in Regenerative Index (RI) in
diaphragm, gastrocnemius medialis (calf), and vastus lateralis
(quadriceps). This is in addition to previously reported
improvements in RI demonstrated in the bicep femoris.
- There were no adverse events and no significant changes in
hematology or clinical chemistry observed.
- Trends to lower creatine kinase levels were noted, a finding
that could be consistent with a Duchenne disease-modifying
treatment.
“We believe the improvements observed in regeneration and muscle
force to close to healthy levels within four months of treatment,
when compared to published natural history data and other
therapeutic interventions in the canine model of DMD, are
groundbreaking,” said Frank Gleeson, Co-founder and CEO of Satellos
Bioscience. “The canine model is considered more severe than mouse
models, and potentially represents a greater test of a treatment’s
utility to translate to humans. We are ecstatic that treatment with
our oral small molecule, SAT-3247, showed such dramatic
improvements. These highly promising results reinforce our belief
in the potential of SAT-3247 to offer a meaningful
disease-modifying medicine to help patients living with
Duchenne.”
The canine model of muscular dystrophy represents a more severe
clinical phenotype and reflects the disease progression observed in
people with DMD. In this pilot study, each animal (n=2) was treated
for four months with a daily oral dose of SAT-3247. This
multiparameter pilot study measured clinical chemistry, hematology,
muscle function, and included a large-scale muscle histology
workup. From the muscle histology, a calculation was made of the
Regenerative Index (RI), a measure of the number of newly
regenerated muscle fibers over the number of damaged and dying
muscle fibers.
The data from this study will be presented in a poster entitled,
“SAT-3247: An Oral Small Molecule Inhibitor Targeting AAK1, a
Critical Effector of Skeletal Muscle Regeneration.” The poster is
available on the Events & Presentations page of the Satellos
website located at ir.satellos.com.
About SAT-3247
SAT-3247 is designed as a once-daily, oral small molecule drug
that targets the root cause of muscle loss in degenerative
diseases, initially targeting Duchenne. SAT-3247 presents a novel
mechanism of action to restore impaired muscle regeneration caused
by the absence of functional dystrophin.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is an inherited disease caused by
mutations in the dystrophin gene that no longer allow the
dystrophin protein to function properly. Consequently, as
discovered by Satellos, muscle repair and regeneration are
impaired. Satellos designed SAT-3247 to restore the process of
muscle repair and regeneration by regulating a
dystrophin-independent pathway with the goal of increasing muscle
function. SAT-3247 is intended to work as a standalone therapeutic
without regard to a patient’s genetic mutation or ambulatory
status. Our approach also has the potential to complement
approaches designed to restore dystrophin production.
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to
developing life-improving medicines to treat degenerative muscle
diseases. Satellos has incorporated breakthrough research in muscle
stem cell polarity into a proprietary discovery platform, called
MyoReGenX™, to identify degenerative muscle diseases where deficits
in this process affect muscle regeneration and are amenable to
therapeutic intervention. With this platform, Satellos is building
a pipeline of novel therapeutics to correct muscle stem cell
polarity and promote the body’s innate muscle repair and
regeneration process. The Company’s lead program is an oral, small
molecule drug candidate in development as a potential
disease-modifying treatment for Duchenne muscular dystrophy.
Satellos is headquartered in Toronto, Ontario. For more
information, visit www.satellos.com.
Notice on Forward-Looking Statements
This press release includes forward-looking information or
forward-looking statements within the meaning of applicable
securities laws regarding Satellos and its business, which may
include, but are not limited to, statements regarding the value of
our DMD program; the advancement of our lead drug candidate into
clinical trials; the expected structure and progress of our
clinical trials and any potential insights or results that may be
obtained from them; the implications of results of our clinical and
pre-clinical trials (including the relevance of pre-clinical
results to utility of our lead drug candidate in humans); the
general benefits of modulating stem cell polarity by administering
small molecule drugs, including our lead drug candidate; its/their
prospective impact on Duchenne patients, patients with other
degenerative muscle disease or muscle injury or trauma, and on
muscle regeneration generally; the utility of our lead drug
candidate and of regenerating muscle by modulating polarity
generally; adoption of Satellos’ approach by the medical community;
and Satellos’ technologies and drug development plans. All
statements that are, or information which is, not historical facts,
including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance,
occurrences or developments, are “forward-looking information or
statements.” Often but not always, forward-looking information or
statements can be identified by the use of words such as “shall”,
“intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”,
“estimate”, “anticipate”, “potential”, “prospective” , “assert” or
any variations (including negative or plural variations) of such
words and phrases, or state that certain actions, events or results
“may”, “might”, “can”, “could”, “would” or “will” be taken, occur,
lead to, result in, or, be achieved. Such statements are based on
the current expectations and views of future events of the
management of the Company. They are based on assumptions and
subject to risks and uncertainties. Although management believes
that the assumptions underlying these statements are reasonable,
they may prove to be incorrect. The forward-looking events and
circumstances discussed in this release, may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting the Company, including, without limitation,
risks relating to the pharmaceutical and bioscience industry
(including the risks associated with preclinical and clinical
trials and regulatory approvals), and the research and development
of therapeutics, the results of preclinical and clinical trials,
general market conditions and equity markets, economic factors and
management’s ability to manage and to operate the business of the
Company generally, including inflation and the costs of operating a
biopharma business, and those risks listed in the “Risk Factors”
section of Satellos’ Annual Information Form dated March 26, 2024
(which is located on Satellos’ profile at www.sedarplus.ca).
Although Satellos has attempted to identify important factors that
could cause actual actions, events or results to differ materially
from those described in forward-looking statements, there may be
other factors that cause actions, events or results to differ from
those anticipated, estimated or intended. Accordingly, readers
should not place undue reliance on any forward-looking statements
or information. No forward- looking statement can be guaranteed.
Except as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Satellos does not undertake any obligation to publicly update or
revise any forward-looking statement, whether resulting from new
information, future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241001367017/en/
Investors: Liz Williams, ir@satellos.com Media: Jessica
Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091
Satellos Bioscience (TSX:MSCL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Satellos Bioscience (TSX:MSCL)
Historical Stock Chart
From Nov 2023 to Nov 2024
